Canopy Growth (CGC) Cash & Current Investments (2017 - 2026)
Canopy Growth (CGC) reported Cash & Current Investments of $265.9 million for Q1 2026, up 190.25% on a YoY basis from $91.6 million in Q1 2025, and little changed sequentially from $266.3 million in Q4 2025.
Canopy Growth (CGC) Cash & Current Investments (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Cash & Current Investments data on file, last reported at $265.9 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments rose 190.25% year-over-year to $265.9 million; the trailing twelve-month figure through Mar 2026 stood at $265.9 million (up 190.25% YoY), and the FY2026 full-year result was $265.9 million, up 190.25% from the prior year.
- Cash & Current Investments steadied at $265.9 million in Q1 2026, from $266.3 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $1.1 billion in Q1 2022 to a low of $91.6 million in Q1 2025.
- A 5-year average of $354.6 million and a median of $187.2 million in 2023 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments plunged 78.65% in 2023 and jumped 190.25% in 2026, its largest moves.
- Tracing CGC's Cash & Current Investments over 5 years: stood at $581.4 million in 2022, then plunged by 76.48% to $136.8 million in 2023, then decreased by 6.65% to $127.7 million in 2024, then jumped by 108.57% to $266.3 million in 2025, then dropped by 0.13% to $265.9 million in 2026.
- Business Quant data shows CGC's Cash & Current Investments at $265.9 million in Q1 2026, $266.3 million in Q4 2025, and $94.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Canopy Growth | 276.52 Mn | 10.60 Mn | - | 265.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 265.93 Mn |
| Dec 31, 2025 | 266.27 Mn |
| Sep 30, 2025 | 94.07 Mn |
| Jun 30, 2025 | 95.29 Mn |
| Mar 31, 2025 | 91.62 Mn |
| Dec 31, 2024 | 127.67 Mn |
| Sep 30, 2024 | 172.93 Mn |
| Jun 30, 2024 | 146.12 Mn |
| Mar 31, 2024 | 131.81 Mn |
| Dec 31, 2023 | 136.76 Mn |
| Sep 30, 2023 | 187.20 Mn |
| Jun 30, 2023 | 403.79 Mn |
| Mar 31, 2023 | 413.25 Mn |
| Dec 31, 2022 | 581.44 Mn |
| Sep 30, 2022 | 876.71 Mn |
| Jun 30, 2022 | 954.63 Mn |
| Mar 31, 2022 | 1.08 Bn |
| Dec 31, 2021 | 1.13 Bn |
| Sep 30, 2021 | 651.29 Mn |
| Jun 30, 2021 | 467.11 Mn |